You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Thyroid cancer

Cabozantinib for treating medullary thyroid cancer

  • Technology appraisal guidance
  • Reference number: TA516
  • Published:  28 March 2018
  • Guidance
  • Tools and resources
  • Information for the public
  • History

On this page

  1. Expected publication
  2. Final appraisal determination
  3. Draft guidance
  4. Assessment report sent for information
  5. Invitation to participate

History

Documents created during the development process.

Expected publication

  • Equality Impact Assessment (Guidance development) (PDF 236 KB)

    Published:
    28 March 2018

Final appraisal determination

  • Final appraisal determination

  • Final appraisal determination document (PDF 320 KB)

    Published:
    15 February 2018
  • Public committee slides (PDF 361 KB)

    Published:
    15 February 2018
  • Committee papers (PDF 2.84 MB)

    Published:
    15 February 2018

Draft guidance

  • Draft guidance

  • Appraisal consultation document (PDF 340 KB)

    Published:
    23 August 2017
  • Public committee slides Clinical slides (PDF 401 KB)

    Published:
    23 August 2017
  • Public committee slides Cost slides (PDF 409 KB)

    Published:
    23 August 2017
  • Committee papers (PDF 20.57 MB)

    Published:
    23 August 2017

Assessment report sent for information

  • Assessment report (PDF 2.33 MB)

    Published:
    14 June 2017

Invitation to participate

  • Final scope (PDF 104 KB)

    Published:
    20 October 2016
  • Final matrix (PDF 97 KB)

    Published:
    20 October 2016
  • NICE's response to comments on the draft scope and provisional matrix (PDF 192 KB)

    Published:
    20 October 2016
  • Equality impact assessment (Scoping) (PDF 61 KB)

    Published:
    20 October 2016
  • Final protocol (PDF 227 KB)

    Published:
    14 June 2017
Back to top